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Abstract
Dual and triple infections with hepatitis
virus C (HCV), B (HBV) and D (HDV) fre-
quently lead to severe liver damage. Hereby we
describe a 38-year-old Caucasian male coin-
fected with HCV (genotype 3a), HBV [positive
hepatitis B surface antigen (HbsAg) and anti-
body to hepatitis B core antigen; negative hep-
atitis B e antigen (HbeAg) and antibody to
hepatitis B e antigen (anti-HBe)] and HDV.
Laboratory diagnostics revealed increased liver
enzymes and histological examination of the
liver showed signs of fibrosis with moderate
inflammation. On therapy with pegIFN-a2b
and ribavirin HCV-RNA was undetectable at
week 8. After week 24 the antiviral therapy was
stopped because of a HBs-seroconversion, the
loss of HbeAg and the detection of anti-HBe.
Furthermore the HCV-RNA was negative. Six
months after successful treatment of the
triple-infection, HCV- and HDV-RNA and
HbsAg remained negative and the liver
enzymes had been completely normalized. In
conclusion, pegylated-interferon plus ribavirin
may be an effective therapy for HCV, HBV and
HDV-coinfected patients.
Introduction
Worldwide, 400 million people suffer from
chronic viral hepatitis B (HBV) and up to 170
million from hepatitis C (HCV).1 Thereby these
infections account largely for the most chronic
and end-stage liver diseases. Coinfections are
not uncommon: 10% of HBV-infected patients
are coinfected with HCV2 and 5% of hepatitis B
surface antigen (HBsAg)-carriers additionally
carry hepatitis D (HDV).3 Dual or triple infec-
tions with these hepatotropic viruses often
lead to more severe liver damage and are
known to increase the risk for hepatocellular
carcinoma (HCC).4-6 Studies indicated that the
antiviral treatment of coinfected patients still
remains a challenge, especially because there
does not yet exist a standard-of-care recom-
mendation. After exclusion of contraindica-
tions, the actual standard therapy for HCV-
mono-infection consists of a combination of
pegylated-interferon alpha (peg-IFNa) plus
ribavirin (RBV).7 Concerning HBV/HCV-coin-
fections, a few preliminary studies showed a
small response to IFN-monotherapy in these
patients,6,8 but Potthoff et al.9 and Yu et al.10
reported on a high effectiveness of peg-IFNa
plus RBV. Much more, they could show similar
efficacy in suppressing HCV RNA in coinfec-
tion in comparison to HCV monoinfection. No
study, however, has yet been presented investi-
gating the efficacy of pegylated peg-IFNa in
HBV/HDV/HCV-coinfected individuals.
Case Report
In August 2009, a 38-year-old Caucasian
male presented to our clinic with elevated liver
enzymes pre-existing for a minimum of three
years. Two months ago, further clinical diag-
nostics were already performed by his general
practitioner. Thereby an HBV/HCV-coinfection
was detected. The patient denied intravenous
drug abuse, sexual risk factors, blood transfu-
sions and a positive family history for infec-
tious and/or other chronic liver diseases.
However we noticed multiple tatoos and the
patient admitted moderate alcohol consump-
tion for many years. Physical examination
revealed no abnormalities. Laboratory diagnos-
tics verified increased liver enzymes [alanine
aminotransferase (ALT) 79 U/L, aspartate
aminotransferase (AST) 181 U/L, gamma-GT
223 U/L]; all other remaining routine parame-
ters including RBC, WBC, platelets, inflamma-
tion parameters, coagulation and thyroid gland
values (TSH, fT3, fT4) were normal. The plas-
ma autoimmune hepatitis antibody panel
(ANA, SLA, LKM, SMA) as well as AMA and
pANCA were negative, and serum IgG, IgA and
IgM levels were not elevated. Microbiological
work-up showed antibodies against HCV (anti-
HCV) with a high-positive viral load of 5.2¥105
copies/mL (genotype 3a). Furthermore serum
hepatitis B surface antigen (HBsAg) was posi-
tive, antibody to hepatitis B surface antigen
(anti-HBs) was negative, antibody to hepatitis
B core antigen (anti-HBc) was positive (anti-
HBc-IgM negative), serum HBeAg and anti-
HBe were negative. Serum HBV DNA level was
low replicative with 1.0¥102 copies/mL, but
antibodies against hepatitis delta virus (IgG
and IgM) were also positive. At this time no
HDV-polymerase chain reaction (PCR) was
determined. An infection with HIV and hepati-
tis A-virus could be excluded. A liver biopsy
was performed and histological examination
revealed portal and periportal fibrosis and a
moderate lobular and portal inflammation
(Grading 4, Staging 2; Metavir-Score A2F2).
Starting October 2009 the patient was treated
with a dual-therapy of pegIFN-a2b 180mg per
week and ribavirin 1200 mg per day. After 8
weeks of treatment HCV-RNA was unde-
tectable with reverse transcription-PCR (RT-
PCR) and HBs-Ag was positive with 6.7 IU/mL
quantitatively. After week 24 HBs- seroconver-
sion was noted evidenced by loss of HBs-Ag
and appearance of anti-HBs (101.7 U/L
quant.). At the same time, we observed the loss
of HBeAg and the detection of anti-HBe.
Furthermore a slow elevation of ALT and AST
was noticeable over the time. Based on an
equally present HCV-RNA-negativity, the dual
antiviral therapy was stopped at week 24. Six
months after successful treatment of the
triple-infection, HCV- and HDV-RNA and
HbsAg still remained negative and the liver
enzymes had been completely normalized
(Figure 1).
Discussion
Dual and triple infections with hepatotropic
viruses (i.e. HBV, HDV, HCV) are frequently
associated with acute or chronic hepatitis with
potential progression to cirrhosis and HCC.4-6
Thus, an effective antiviral therapy is essential
to provide the affected patients with a good
prognosis. Unfortunately there do not exist any
coherent clinical trials, which could form a
basis for a generally valid standard-of-care rec-
ommendation. To our knowledge, the present-
ed case is the first showing a sustained recov-
ery from a coinfection with HCV, HBV and HDV
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after antiviral treatment with peg-IFNa-2b and
ribavirin for 24 weeks. The literature contains
multiple studies about different therapeutic
approaches for patients with viral coinfections:
Villa et al.11 reported on 30 patients with
HBV/HCV-coinfection treated with IFN-mono.
The results showed that in a proportion of
patients IFN could lead to both HBV and HCV
viral clearance, especially if higher doses of
standard-IFNa were used. On the other hand,
Zignego et al.8 concluded that HCV patients
with occult hepatitis B had significantly lower
biochemical and virological response rates to
IFN as compared to those who were HBV DNA
negative. Several trials could show synergistic
beneficial effects between standard IFN and
RBV for the treatment of chronic hepatitis C.
Therefore a few study groups investigated the
effect of this combination regimen for patients
with HBV/HCV-coinfecion. In these patients
they observed similar sustained virological
response (SVR) rates (between 43% and 69%)
in comparison to HCV-monoinfection.12-14 In
2009 Liu et al.15 performed the largest, random-
ized, controlled prospective study with pegylat-
ed interferon and ribavirin for 161 patients
with HBV and HCV-coinfection. They could
show high HCV-SVR (up to 83%) and good
HBV-response rates (HBsAg loss (N=18, 11%)
and HBV DNA negativity (N=38, 56%)).
However, in agreement with two other previ-
ous studies,9,10 they also showed a high HBV
reactivation rate (37%) among the 77 patients
with undetectable HBV DNA at baseline. Our
presented patient suffered not only from a dual
infection with HCV and HBV but also from
HDV. Hepatitis D is considered to be the most
severe form of viral hepatitis in humans,
affects only HBV-infected patients and is often
accompagnied with fulminant hepatitis and in
chronic liver disease with early decompensa-
tion.16,17 Actually, the only approved treatment
regimen for hepatitis D is a mono-therapy with
peg-IFN.18-20 Oral antiviral agents (i.e. rib-
avirin, lamivudine) are ineffective.21-23
Furthermore, the addition of lamivudine or rib-
avirin to IFN has not improved efficacy, as
compared to the use of interferon alone.24-27
The recently presented Hep-Net-International
Delta Hepatitis Intervention Trial (HIDIT)28
investigated the safety and efficacy of peg-
IFNa-2a plus adefovir dipivoxil, as compared to
either drug alone, in patients with chronic
HDV infection. After 48 weeks of treatment
with peg-IFNa-2a (mono or in combination
with the oral antiviral drug adefovir dipivoxil)
about one quarter of patients had clearance of
HDV RNA 24 weeks after the end of treatment.
In addition, 7% of the patients had normalized
ALT associated with a complete HDV RNA-
clearance. However, after treatment with ade-
fovir dipivoxil alone none of the patients had
clearance of HDV RNA. Concerning the coinci-
dent HBV-infection, the combination of pegin-
terferon alfa-2a and adefovir resulted in a
decline in the HBsAg level of at least 1 log10 IU
per milliliter in approximately one third of
patients. So far, there are no data available on
a complete virological response after treat-
ment with peg-IFN and RBV in triple-infected
(HCV/HBV/HDV-coinfected) patients. Zuberi et
al.29 reported on 246 patients with HBV, there-
of 29 (11.8%) patients with positive anti-HBc
IgG, anti-HDV and anti-HCV. After 48 weeks of
therapy HBV DNA was cleared in 4 (13.8%)
patients with positive HBV DNA (without HCV-
RNA). Patients who did present with both, HBV
DNA and HCV RNA, HCV was undetectable in 2
(6.9%) while HBV was not cleared in any case.
The results of viral antibodies (i.e. HbsAg,
anti-HBc) unfortunately were not described in
this study. Gozlan et al.30 described a patient
with a quadruple infection of HIV/HCV/HBV
and HDV. Due to an active HCV-infection
(HCV-RNA>3¥106 IU/mL, Metavir Score A2 F1
and fluctuating liver enzymes) an antiviral
therapy of pegIFN and RBV was started. After 6
months of therapy HCV-RNA was still
detectable, but the authors could observe
HBsAg-clearance, anti-HBs seroconversion
and negative serum HBV DNA (HBV viral load
6 months before starting pegIFN/RBV:
<125.000 IU/mL). Suprisingly, HBsAg-clear-
ance came along with an extensive HDV repli-
cation (HDV RNA 9.3¥106 copies/mL) resulting
in clearance of HDV RNA 6 months later. The
authors suggested that the sustained virologi-
cal response of HBV and HDV under antiviral
treatment might be a result of the proper
immune response of the patient, which he
developed a few months before initiation of
pegIFN. This immune response was detected
by an increase of aminotransferases and
maybe was enhanced by the interferon treat-
Case Report
Figure 1. Biochemical and virological profile of the patient. The horizontal line indicates
the upper limit of normal for alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST). HBV, hepatitis B virus; HCV, hepatitis C virus; HDV hepatitis D virus;
HBeAg, hepatitis B e antigen; HBe, antibody to hepatitis B e antigen; anti-HBc antibody
to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; anti-HBs, antibody to
hepatitis B surface antigen.
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ment resulting in HBV clearance. The patient
presented here also showed increased liver
enzymes before starting antiviral therapy.
Thus, we cannot exclude the possibility that
our therapeutic success may be an expression
of a spontaneous immune response of the
patient already at the start of pegIFN and RBV.
This effect might be independent of the viro-
logical response due to the antiviral therapy
but cannot be differentiated. Nonetheless, this
has never been described in patients with
triple infections of HCV/HBV and HDV.
According to previous studies,30-33 HCV was the
dominant virus in our case. Based on the high
viral load of the hepatitis C virus and good
results in double-infected patients9,10,15 we ini-
tially recommended a combinated antiviral
therapy with peg-IFN and RBV. Fortunately,
after 8 weeks of treatment the HCV RNA was
undetectable and after another 16 weeks we
achieved a complete seroconversion from
HBsAg to Anti-HBs. Six months after the dual
antiviral therapy the HDV RNA remained neg-
ative and there were no evidences for HBV-
reactivation as has been reported in previous
studies.9,10 Because of this suprising result no
nucleotide analog reverse transcriptase
inhibitor (i.e. adefovir) was started. Studies
indicate an inverse relationship between HBV
and HCV replication and an alternative domi-
nant role of HBV and HCV.32,34,35 Some authors
observed a dominated role of the hepatitis C-
virus with suppression of the HBV replica-
tion.35 Others showed that HBV DNA replica-
tion inhibits HCV RNA replication among dual-
ly infected patients.36 Furthermore, many of
these studies demonstrate that successful
clearance of one virus may lead to reactivation
of the other.37 In conclusion, our case report
emphasizes that a dual therapy with peg-IFNa
plus ribavirin can constitute a successful treat-
ment in HCV/HBV/HDV-coinfected patients,
not only with a sustained virological response
of HCV-RNA but also with induction of HBsAg
seroconversion and clearance of HDV-RNA.
Continuous monitoring of the patient’s symp-
toms, the blood count, the transaminases and
virological antibodies are essential for a suc-
cessful treatment of viral hepatitis.
Furthermore the optimal treatment duration
has to be adapted to every individual patient.
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